


Express Mail Label No.: EV058075152US

Date of Deposit: March 5, 2002

Attorney Docket No.: 15966-575B (Cura-75B)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga et al.

SERIAL NUMBER: 09/679,740

EXAMINER: Not Yet Assigned

FILING DATE: October 5, 2000

ART UNIT: 1645

FOR: Endozepine-Like Polypeptides and Polynucleotides Encoding Same

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (1 page) in duplicate;
3. Copies of cited references A2, B1-B3 and C39-C52; and
3. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 15966-575B (Cura-75B). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241


Dated: March 5, 2002

RECEIVED

MAR 12 2002

TECH CENTER 1600/2900

03-06-02 03A0 0210 1645



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Prayaga et al.

SERIAL NUMBER: 09/679,740

EXAMINER: Not Yet Assigned

FILING DATE: October 5, 2000

ART UNIT: 1645

FOR: Endozepine-Like Polypeptides and Polynucleotides Encoding Same

BOX IDSAssistant Commissioner for Patents
Washington, D.C. 20231RECEIVED
MAR 12 2002
TECH CENTER 1600/2900**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Supplemental Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action, based on the merits, in the above-identified application. Accordingly, no fee is believed due at this time.

A copy of each of the above-identified information is enclosed. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Supplemental Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 15966-575B (Cura-75B))


Respectfully submitted,


Ivor R. Elrifi (Registration No. 39,529)
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 5, 2002
TRA 1637288v1

Date of Deposit: March 5, 2002

Please type a plus sign (+) in this box



PTO/SP-0297

Approved for use through 9/30/00. OMB 065-0051

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/679,740
Filing Date	October 5, 2000
First Named Inventor	Prayaga et al.
Group Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	15966-575B (Cura-75B)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A2	5,945,033	08/31/99	Yen			11/12/96

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 86/04239	Oncogen	July 31, 1986	
	B2	WO 97/15671	Board of Regents, The U. of Texas System	May 1, 1997	
	B3	WO 98/06847	Incyte Pharmaceuticals, Inc.	Feb. 19, 1998	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C39	EMBL Database Accession No.: HSZZ11676 (April 18, 1997)
	C40	EMBL Database Accession No.: AC008434 (August 4, 1999)
	C41	Herzig et al. (1995). <i>Gut</i> 37 (Suppl. 2): A70.
	C42	Ivell et al. (2000). <i>Gene</i> 255 : 335-345.
	C43	Knudsen et al. (1993). <i>Mol. and Cell. Biochem.</i> 123 : 129-138.
	C44	Leprince et al. (1998). <i>J. Med. Chem.</i> 41 : 4433-4438.
	C45	Marquardt et al. (1986). <i>J. Biol. Chem.</i> 261 : 9727-9731.
	C46	EMBL Database Accession No.: AA843364 (March 10, 1998)
	C47	Pusch et al. (1999). <i>Gene</i> 235 : 51-57.
	C48	Reddy and Kulkarni (1998). <i>Psychopharmacology</i> 137 : 391-400.
	C49	Swinnen et al. (1996). <i>DNA and Cell Biol.</i> 15 : 197-208.
	C50	Tonon et al. (1994). <i>Medecine/Sciences</i> 10 : 433-443.
	C51	Venturini et al. (1998). <i>Regulatory Peptides</i> 74 : 31-34.
	C52	International Search Report for PCT/US00/41077, mailed October 15, 2001.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.